Skip to content

Studying the effect of almond on Alzheimer's disease

Evaluation of the effectiveness of "Prunus dulcis" on Alzheimer's diseases

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231031059912N1
Enrollment
60
Registered
2024-01-22
Start date
2020-12-21
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer. Dementia in Alzheimer disease

Interventions

Intervention 1: "Intervention group": Sweet almond obtained from central Zagros regions in the amount of 10 grams per day, slightly sweetened with cantaloupe powder (about one tablespoon) were consume

Sponsors

Vice Chancellor for Research & Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed based on history and questionnaire and examination and paraclinic under the supervision of psychiatrist or neurologist or geriatrics specialist Having no other psychiatric disease causing dementia other than Alzheimer's based on the opinion of a specialist Not having severe non-psychiatric and non-neurological diseases based on the opinion of a specialist Not abusing substances or drugs (except nicotine and caffeine) such as narcotics or stimulants Informed written consent of the patient or the patient's guardian to enter the plan

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes mellitus because the almonds are slightly sweetened with candy

Design outcomes

Primary

MeasureTime frame
Change in score of MMSE and FAST questionnaires, CDR and MoCA and sleep questionnaire. Timepoint: Completing the questionnaire at the beginning of the study (before the start of the intervention) and 3 months after starting to consume almonds. Method of measurement: MMSE? MoCA? CDR? FAST and sleep questionnaires.

Secondary

MeasureTime frame
Complications. Timepoint: The time periods of completing the questionnaire as a secondary outcome, at the beginning of the study (before the start of the intervention) and 3 months after consuming almonds. Method of measurement: MMSE and FAST, CDR and MoCA and sleep questionnaires.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Mohajeri

Iran University of Medical Sciences

Mo_mohajeri@yahoo.com+98 21 86701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026